Meeting
2013 Gastrointestinal Cancers Symposium
A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC0902).
Authors
Masaaki Takeuchi
Department of Surgery, Social Insurance Tagawa Hos
Masaaki Takeuchi , Yutaka Ogata , Takaho Tanaka , Atsushi Kaibara , Yasunori Emi , Hiroshi Saeki , Eiji Oki , Noriaki Sadanaga , Tetsuya Kusumoto , Tetsuo Touyama , Hiroo Matsushita , Mototugu Shimokawa , Hideo Baba , Kazuo Shirouzu , Yoshihiko Maehara
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Cancers of the Colon and Rectum
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
UMIN000003915
Citation
J Clin Oncol 31, 2013 (suppl 4; abstr583)
DOI
10.1200/jco.2013.31.4_suppl.583
Abstract #
583
Poster Bd #
E31
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Bevacizumab (B) + bi-weekly capecitabine (C) and oxaliplatin (O) (XELOX2) or FOLFOX4 in first-line treatment of metastatic colorectal cancer (mCRC): Final results of a multicenter randomized phase II trial of the Gruppo Oncologico dell’Italia Meridionale (GOIM protocol 2802).
First Author: Evaristo Maiello
Poster
2020 Gastrointestinal Cancers Symposium
Quattro-II study: A multicenter randomized phase II study comparing capoxiri plus bevacizumab with FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer as the first-line treatment.
First Author: Akihito Tsuji
Poster
2016 ASCO Annual Meeting
Effect of pharmacogenetic-based selection of first-line chemotherapy on response rate and R0 surgery in metastatic CRC patients.
First Author: Albert Abad
Poster
2015 Gastrointestinal Cancers Symposium
Improving safety in first-line metastatic colorectal cancer (MCRC) therapy with bevacizumab: Modified FOLFOX7 versus XELOX2—Results of the induction phase of the GERCOR DREAM randomized phase III study.
First Author: Christophe Tournigand